Shanghai – June 10, 2026 – SIMR Biotech today announced that its abstract titled “Safety and Efficacy of SR750 in Patients with Trigeminal Neuralgia: A Double-Blind, Randomized, Placebo-controlled, Phase 2 Study” has been accepted for presentation as a Late‑breaking ePoster at the 12th Congress of the European Academy of Neurology (EAN 2026), to be held in Geneva, Switzerland, from June 27–30, 2026.
The accepted presentation will highlight Phase 2 clinical data showing that SR750 achieved a statistically significant and clinically meaningful reduction in pain versus placebo in patients with trigeminal neuralgia over a 6-week treatment period, with supportive findings across secondary endpoints and a favorable safety and tolerability profile.
SR750 is a first-in-class peripheral α5-GABA_A receptor NAM being developed as a non-opioid treatment for peripheral neuropathic pain, including trigeminal neuralgia, painful diabetic peripheral neuropathy (PDPN), painful lumbosacral radiculopathy (PLSR), and postherpetic neuralgia (PHN).
“Acceptance into the EAN 2026 Late-breaking Session highlights the significance of our Phase 2 findings in trigeminal neuralgia,” said Dr. Fei Wang, Vice President of R&D at SIMR Biotech. “We believe SR750 has the potential to offer a differentiated non-opioid treatment option for patients living with neuropathic pain.”
EAN 2026 Presentation Details
· Session: EPO-071 | Late-breaking Session
· Date/Time: Monday, 29 June 2026 | 14:15–15:15 CEST
· Location: ePoster Area, Booth A1, Palexpo, Geneva, Switzerland
About SR750 and SIMR Biotech
SIMR Biotech is focused on innovative non-opioid therapies for pain. The company is advancing multiple pipelines of differentiated candidates for neuropathic and other pain indications, including SR750, a first-in-class peripheral α5-GABA_A receptor NAM supported by Phase 2 proof-of-concept data in trigeminal neuralgia, and SR2162, another clinical-stage pain candidate with a differentiated mechanism and broad potential across acute and chronic pain indications.
